New Jersey-based medical technology developer Becton Dickinson (BD) has agreed to acquire Safety Syringes.
The Franklin Lakes company will buy the California-headquartered anti-needlestick device developer in a bid to enhance its offering, enabling it to provide passive safety offerings to prefillable syringe customers.
William Kozy, executive vice president of BD said: "This acquisition is intended to provide our BD Medical - Pharmaceutical Systems unit with additional safety features for prefillable syringes, helping to protect against accidental needlesticks by providing safer injections for healthcare workers and end users."
Claude Dartiguelongue, President of the buyer’s pharmaceutical systems division added: "We believe BD's prefillable syringe expertise, combined with Safety Syringes' product portfolio and device development expertise, will enable new and innovative safety technology development to prepare the next generation of safety-engineered prefillable syringes."
Financial details of the deal, which is subject to regulatory approvals and is expected to complete by the end of fiscal 2012, have not been disclosed.
Safety Syringes is based in Carlsbad and headed by chief executive Peter Nolan.
Founded in 1990, the company has developed safety technology with applications including prefilled pharmaceutical glass, disposable plastic hypodermic, and dental syringes, as well as blood collection devices and IV catheters.
It is currently marketing products under the UltraSafe brand and according to its website, is the market leader for needle safety devices for prefilled glass syringes.
BD develops, makes and sells medical devices, instrument systems and reagents and is a leader in its field, according to its website.
The company was founded in 1897 and operates through three divisions, known as BD Medical, BD Diagnostics and BD Biosciences.
With offices in over 50 countries worldwide, the business recorded revenue of USD 1.99 billion for the second quarter of fiscal 2012, ending 31st March.
The figure is down 3.6 per cent on the same period in 2011.
© Zephus Ltd
|